Criteria 1. Unparterned 2. Not enough cash to bring the product to market 3. Lets say at least started Phase 3 trials 4. Its on a product basis so if company a has 2 unparterned Phase 3 products and not enough cash then an entry for each would be appropriate
Stock Product Stage Comments ----- --------------- --------------------- ----------------------------- NTII Viprinex Phase 3 Interim analysis January '09. Stroke Drug, high chance of failure. BPAX Libigel Phase 3 ~2010 Submit Adequate Safety? EPIX Vasovist PDUFA 12/30/08 FDA initially rejected saying 2 more studies needed. Allowed reread company states results very positive. Looking to sell outright on approval. RPRX Proellex Phase 3 Uterine fibroids CHTP Droxidopa Pivotal Phase III Orthostatic hypotension. Results expected 02/09 JAV Dyloject Phase III Approved in UK. Post operative Pain (injectable) JAV Dyloject Phase III Acute moderate-to-severe pain (intranasal)
----- 1. Reply to this post copying all the text 2. Please put [ pre ] at the begining of the table without surrounding spaces. 3. Please put [ /pre ] at the end of the table without surrounding spaces.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.